

正誤表

雑誌「産婦人科の実際」第74巻7号（2025年7月号）につき内容の更新がございました。下記のとおり訂正いたします。

2025年7月

金原出版株式会社

記

頁	691
訂正箇所	文献
訂正前	1) <u>Lorusso D et al : DS-6000a in advanced ovarian cancer : phase 1 expansion cohort (U101). Ann Oncol 34 (Suppl 2) : LBA77, 2023</u> 2) Santin AD et al : Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03) : analysis in patients with advanced endometrial cancer. J Clin Oncol 42 : 3421-3429, 2024 3) <u>Wang D et al : Sacituzumab tirumotecan in endometrial and ovarian cancer : phase 2. Ann Oncol 35 (Suppl 8) : Abstr 777, 2024</u> 4) <u>Oaknin A et al : Datopotamab deruxtecan in gynecologic cancers : TROPION-PanTumor03. Ann Oncol 35 (Suppl 5) : S547-548, 2024</u> 5) <u>Banerjee S et al : Rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer : RAINFOL-01. Presented at : ESMO Gynaecol Cancers Congr ; Feb 23-25 ; Abstract LBA02, 2024</u> 6) <u>Gaillard S et al : Puxitatug samrotecan (AZD8205) in endometrial cancer : BLUESTAR study. Presented at : SGO Annu Meeting ; Mar 14-17 ; Abstract 933087, 2025</u>
訂正後	1) Moore KN et al : Raludotatug deruxtecan (R-DXd ; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC) : Subgroup analysis of a first-in-human phase I study. Ann Oncol 34 (Suppl 2) : S510, 2023 2) Santin AD et al : Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03) : analysis in patients with advanced endometrial cancer. J Clin Oncol 42 : 3421-3429, 2024 3) Wang D et al : Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) : A phase II study. Ann Oncol 35 (Suppl 2) : S548, 2024 4) Oaknin A et al : Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC) : Results from the phase II TROPION-PanTumor03 study. Ann Oncol 35(Suppl 2) : S547-548, 2024 5) Lee EK et al : Rinatabart sesutecan (Rina-S) for patients with advanced ovarian cancer : Results from dose expansion cohort B1 of a phase 1/2 study. Presented at : SGO 2025 ;

	Abstract 809034, 2025 6) Gaillard S et al : Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer : A first-in-human Phase 1/2a study. Presented at : SGO 2025 ; Abstract 933087, 2025
--	--

以上